Table 1 Baseline characteristics.
| Single IVTA injection (%) | Repeated IVTA Injections (%) | Comparison of single v repeated p values | |
|---|---|---|---|
| Sample size | 528 | 43 | |
| Sex | 0.70 | ||
| Male | 242 (45.8%) | 21 (48.8%) | |
| Female | 286 (54.2%) | 22 (51.2%) | |
| Age | |||
| Mean | 70.26 | 69.53 | 0.70 |
| Range | 14–95 | 44–89 | |
| SD | 11.77 | 10.55 | |
| Pre‐existing glaucoma | 90 (17.0%) | 7 (16.3%) | 0.89 |
| Use of antiglaucoma drugs | 43 (47.8%) | 6 (85.7%) | 0.007 |
| Average number of drugs (SD) | 0.29 (0.72) | 0.56 (0.98) | |
| Hypertension | 297 (56.3%) | 18 (41.9) | 0.07 |
| Diabetes | 298 (56.4%) | 29 (67.4) | 0.16 |
| Use of topical steroids | 29 (5.5%) | 4 (9.3) | 0.52 |
| Baseline IOP (mm Hg) (SD) | 15.51 (3.63) | 15.53 (3.24) (range 4–22) | 0.97 |
| Baseline VA (logMAR) (SD) | 0.809 (0.477) | 0.879 (0.367) | 0.44 |
| Diagnoses | |||
| NPDR | 270 (51.1%) | 18 (41.9%) | |
| PDR | 89 (16.9%) | 8 (18.6%) | |
| BRVO/CRVO | 69 (13.1%) | 5 (11.6%) | |
| CMO | 39 (7.4%) | 11 (25.6%) | |
| Uveitis | 3 (0.6%) | None | |
| Other | 58 (11%) | 1 (2.3%) |
NPDR, non‐proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; CMO, cystoid macular oedema.